Announcements Trials
Browse Landscape

Status

Completed 623Terminated 242Recruiting 193Active not recruiting 104Unknown 64Withdrawn 30Not yet recruiting 24Suspended 6Available 2Approved for marketing 2No longer available 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 5Pancreatic Neoplasms 5Multiple Myeloma 5Melanoma 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Glioblastoma 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Primary Myelofibrosis 2Non-Muscle Invasive Bladder Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2

Interventions

tempol 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Available × INDUSTRY × Neoplasm Metastasis × Clear all
NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Pfizer

Available
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT05491928 2022-09-01

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Matrix Biomed, Inc.

Available
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡